Eli Lilly and Company (India) Pvt. Ltd. today announced the launch of its recently approved diabetes treatment Trulicity (dulaglutide) in India. Trulicity is the first once-weekly, injectable medication designed to improve blood sugar control in adults with type 2 diabetes.
Trulicity is a once weekly injectable type 2 diabetes treatment. It’s not insulin, belongs to a different class called GLP-1 receptor agonists and comes in a single-dose pen which doesn’t require mixing or measuring.
Trulicity is part of a class of drugs known as a glucagon – like peptide (GLP-1) receptor agonists. It is not insulin and mimics the effects of GLP-1, a natural hormone that helps keep blood sugar levels normal, by helping the body release its own insulin after food intake.
Trulicity comes in an easy to use, single-dose pen that does not require mixing or measuring and can be administered at any time of the day, independent of meals.
India is among the first few countries in the world and only third in Asia (after UAE and Japan) to launch Trulicity. It received US FDA approval in September 2014 and EU approval in November 2014.